Innovación en el tratamiento de los Sarcomas de Partes Blandas - page 21

Diseño: Alternativas al fase III tradicional?

•

rEECur

ciclofosfamida 250 mg/m D1-5 & IV

topotecan 0.75 mg/m D1-5

irinotecan 50 mg/m D1-5 &

temozolomida 100 mg/m D1-5

ifosfamida 3000 mg/m D1-5

gemcitabina 1000 mg/m D1,8 & IV

docetaxel 100 mg/m D8

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,11,12,13,14,15,16,17,18,19,20 22,23,24,25,26,27,28,29,30,31,...36